Increased platelet aggregation and activation in peripheral arterial disease

Robless, P; Okonko, Darlington O.; Lintott, Patrick; Mansfield, Averil O.; Mikhailidis, DP; Stansby, Gerard

doi:10.1053/ejvs.2002.1794

Cited by 97 publications

(86 citation statements)

References 42 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Consistent with previous studies, [19][20][21] we have demonstrated that platelet and monocyte activation is increased in patients with PAD. We have shown for the first time, to our knowledge, that patients undergoing surgery for CLI have even greater levels of platelet and monocyte activation than patients being treated for acute MI.…”

Section: Discussionsupporting

confidence: 93%

“…Several studies have assessed platelet activation in peripheral atherosclerosis and demonstrated a progressive increase in activation with increasing severity of disease. [19][20][21] However, there have been relatively few reports of platelet activation and cellular inflammation at the time of operation, [22][23][24] and none, to our knowledge, have compared PAD patients with other high-risk populations.…”

mentioning

confidence: 99%

See 1 more Smart Citation

Perioperative platelet and monocyte activation in patients with critical limb ischemia

Burdess

Nimmo

Campbell

et al. 2010

Journal of Vascular Surgery

View full text Add to dashboard Cite

show abstract

Section: Discussionsupporting

confidence: 93%

mentioning

confidence: 99%

Perioperative platelet and monocyte activation in patients with critical limb ischemia

Burdess

Nimmo

Campbell

et al. 2010

Journal of Vascular Surgery

View full text Add to dashboard Cite

show abstract

“…This risk is mediated in part by increased platelet reactivity that predisposes to thrombus formation in response to plaque erosion and rupture [35,36]. The use of antiplatelet therapy in patients with symptomatic PAD has been associated with a reduction in MACE, including MI and nonfatal stroke [37].…”

Section: Antithrombotic Therapymentioning

confidence: 99%

Medical Therapy in Peripheral Artery Disease and Critical Limb Ischemia

Foley

Waldo

Armstrong

2016

Curr Treat Options Cardio Med

View full text Add to dashboard Cite

Peripheral artery disease (PAD) comprises atherosclerosis of the aorta and lower extremities. Many patients with PAD are asymptomatic, while others present with intermittent claudication (IC) or critical limb ischemia (CLI). Defined as rest pain or tissue loss that persists for >2 weeks, CLI represents the most severe clinical manifestation of PAD and is associated with an increased risk of limb loss and death. Patients with PAD, including those with CLI, are underdiagnosed and undertreated. In addition to smoking cessation, medical therapy with an antiplatelet agent and statin is recommended for all patients with PAD. Regular exercise has been shown to improve walking distance and quality of life in patients with symptomatic PAD and should be incorporated into each patient's treatment plan. In patients who have CLI and in those with persistent lifestyle-limiting claudication despite optimal medical therapy and an exercise program, revascularization is indicated for limb salvage and symptom relief, respectively. Consensus guidelines currently support an endovascular first approach to revascularization in the majority of cases. Surgical procedures provide an alternative to endovascular therapy in select cases.

show abstract

“…Adverse indicators of platelet function in PAD have been reported, including increased β-thromboglobulin (83), increased platelet aggregation (84,85), increased fibrinogen binding (30), increased platelet P-selectin and soluble P-selectin (86,87), and an increase in platelet microparticles (88). Platelet and soluble P-selectin levels also independently predict disease severity in PAD (88).…”

Section: Plateletsmentioning

confidence: 99%

Peripheral arterial disease and Virchow’s triad

Bennett

Silverman

Gill³

et al. 2009

Thromb Haemost

View full text Add to dashboard Cite

SummaryPeripheral arterial disease (PAD) is an important global healthcare problem associated with considerable morbidity and mortality. This disease is an important manifestation of atherosclerosis and the pathophysiological processes involved in its development, progression and complications are atherothrombosis and thromboembolism. Over 150 years ago, Virchow described a triad of abnormalities (abnormal blood flow, abnormal vessel wall and abnormal blood constituents) associated with KeywordsArterial thrombosis, clinical studies, risk factors thrombus formation (thrombogenesis). An improvement in biochemical techniques has allowed quantification of various components of Virchow's triad, and as a consequence, there has been increasing interest in the measurement of such biomarkers in understanding the development and progression of PAD, as well as its symptomatic complications. This review discusses quantifiable components of Virchow's triad that have been associated with PAD and their clinical utility as risk factors for PAD.

show abstract

Increased platelet aggregation and activation in peripheral arterial disease

Abstract: this study provides further evidence that platelet hyperactivity is present in patients with PAD despite the use of antiplatelet therapy. Further antiplatelet strategies may be indicated to protect these patients.

Cited by 97 publications

References 42 publications

Perioperative platelet and monocyte activation in patients with critical limb ischemia

Perioperative platelet and monocyte activation in patients with critical limb ischemia

Medical Therapy in Peripheral Artery Disease and Critical Limb Ischemia

Peripheral arterial disease and Virchow’s triad

Contact Info

Product

Resources

About